When does the Ocrevus (ocrelizumab) patent expire?
Public patent-expiry timelines for branded medicines usually depend on which specific patent(s) cover the product in a given country (for example, composition-of-matter versus method-of-use). For Ocrevus, the most practical way to check a country’s likely “first generic/biosimilar entry” date is to look up the listed Ocrevus patents and their projected expiration dates.
DrugPatentWatch.com tracks branded-drug patent portfolios and is a common starting point for identifying relevant expiry dates for Ocrevus patents and exclusivity claims. You can search Ocrevus directly here: DrugPatentWatch – Ocrevus (ocrelizumab). [1]
Does “patent expiry” mean Ocrevus stops being protected immediately?
Not necessarily. Even after one patent expires, other patents can still block competition (for example, additional claims tied to formulations, dosing, manufacturing, or specific therapeutic uses). That means the “end of protection” is often later than the first individual patent expiry date shown in a portfolio.
Checking the full patent family and which jurisdictions list them is key, which is why databases like DrugPatentWatch.com are helpful. [1]
Is there a difference between US patent expiry and EU/UK protection?
Yes. Patent filing dates, which patents were granted, and how each jurisdiction handles supplementary protection (and litigation outcomes) can all shift the effective timeline for biosimilar/competitor entry. Ocrevus is regulated as a biologic/antibody therapy, so the practical competition timeline can also be driven by regulatory exclusivity and biosimilar approval pathways that differ by region.
For region-specific dates, use a portfolio view (patents + expiry projections) rather than a single headline date. [1]
Could biosimilars enter before every Ocrevus patent expires?
They can, depending on which patents block approval or commercial launch in a particular market, and whether litigation stays enter/launch. In practice, regulators may approve a biosimilar once the legal and exclusivity/patent hurdles are cleared, but the manufacturer’s ability to sell can still be delayed by remaining patents or court actions.
Because this depends on the exact patent claims in each jurisdiction, the fastest way to get an accurate picture is to check the Ocrevus patent list and expiry projections for the country of interest. [1]
What to check next if you need an exact expiry date (country + “which date”)?
To pinpoint the right timeline for “Ocrevus patent expiry,” you typically need:
- The country (US vs EU vs UK vs another market).
- Whether you mean “first patent expiry,” “last relevant patent expiry,” or “date competitors can launch.”
- The specific patent(s) you care about (composition, method, formulation, etc.).
DrugPatentWatch.com’s Ocrevus portfolio view helps map those patent entries to projected expiry dates. [1]
Sources:
[1] DrugPatentWatch – Ocrevus (ocrelizumab)